EC
BCYC

EntryPoint Capital’s Bicycle Therapeutics BCYC Stock Holding History

EntryPoint Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$297K Buy
+63,906
New +$365K 0.09% 474
2025
Q2 		– Sell
-28,857
Closed -$245K – 624
2025
Q1 		$245K Sell
28,857
-15,016
-34% -$177K 0.11% 439
2024
Q4 		$614K Buy
+43,873
New +$940K 0.26% 52
2024
Q1 		– Sell
-18,495
Closed -$334K – 1436
2023
Q4 		$334K Buy
+18,495
New +$306K 0.32% 16

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EntryPoint Capital's BCYC Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Bicycle Therapeutics (BCYC) in Q1 2026: 63,906 shares worth $297K. The stake represents 0.09% of the portfolio and ranks #474 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in BCYC as recently as Q1 2025.

EntryPoint Capital first reported a position in BCYC in Q4 2023 and has held it in 4 quarters since. The position peaked at $614K in Q4 2024. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • EntryPoint Capital held 63,906 shares of Bicycle Therapeutics worth $297K as of Q1 2026.
  • Bicycle Therapeutics was a new EntryPoint Capital position in Q1 2026.
  • Bicycle Therapeutics made up 0.09% of EntryPoint Capital's portfolio in Q1 2026, its #474 holding.
  • EntryPoint Capital first reported a position in Bicycle Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • EntryPoint Capital's Bicycle Therapeutics position peaked at $614K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.